Parameters | Groups | Baseline | Week 12 | Week 24 |
---|---|---|---|---|
24 h UP (g/24 h) | TSF | 1.0 ± 0.7 | 0.5 ± 0.5a | 0.5 ± 0.5a |
Placebo | 0.9 ± 0.6 | 0.6 ± 0.6 | 0.7 ± 0.7 | |
BUN (mmol/L) | TSF | 6.0 ± 1.7 | 6.0 ± 1.7 | 6.0 ± 1.9 |
Placebo | 6.1 ± 1.1 | 6.9 ± 1.6 | 7.2 ± 1.7 | |
Scr (μmol/L) | TSF | 74.9 ± 20.7 | 72.6 ± 22.6 | 73.5 ± 18.9 |
Placebo | 79.4 ± 18.2 | 84.0 ± 17.4 | 83.1 ± 16.4 | |
eGFR (ml/min/1.73 m2) | TSF | 104.1 ± 32.8 | 102.7 ± 37.7 | 97.3 ± 25.8 |
Placebo | 96.2 ± 30.0 | 91.3 ± 30.1 | 92.3 ± 32.2 | |
ln plasma L-FABP (μg/ml) | TSF | 1.7 ± 1.0 | 1.3 ± 1.3 | 1.5 ± 0.9 |
Placebo | 1.6 ± 1.2 | 0.8 ± 1.4 | 1.2 ± 1.0 |